SBIR/STTR Research Award

Radiological Image Enhancement with Tantalum, a Heavy Z Atom

Award identifier b6a68cfdcaa57c1c4ea5d6bd62a95adaa5976d8f25921026e469f198ec849b57Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$100,000

Program and phase

SBIR · Phase I

Award year

2008

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
MICROBEAM THERAPY, LLC
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
PHS2007-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Agents containing one or more heavy Z (high atomic number) atoms offer substantial improvements in contrast and spatial resolution, while reducing the overall patient radiation dose. The objective of this proposed resea rch effort is to prepare well-defined tantalum compounds as radiographic agents. Tantalum (Ta) has been used for decades as both a metallic implant and radiographic marker. The principal focus will be on cluster compounds that contain several tantalum atom s, thus enabling high X-ray attenuation. These compounds will be synthesized, characterized, modified, and screened for properties predictive of physiological compatibility. The ideal tantalum-based contrast agent (1) provides high X-ray attenuation and th erefore high contrast, (2) is stable under physiological conditions, (3) is available in high concentration, (4) is non- toxic, (5) is injected easily, (6) resides in the ROI (Region of Interest) for a sufficient length of time to allow imaging, and (7) is then completely excreted from the body. Our hypothesis is that suitable contrast agents can be developed using tantalum as the heavy atom. The targeted properties of the Ta-containing materials are (1) a tantalum-dense cluster, (2) sufficiently modifiable surface to attain the other agent requirements. Promising agents will be evaluated as saturated solutions by X-ray absorption analysis. Signal to background determination will enable a ranking of the cluster-surface systems. Required dose scenarios will b e extrapolated from the analysis of dilution series. After the in vitro testing is completed we will proceed to Phase II with animal trials to characterize safety and efficacy in vivo. Once these are established, then we will hopefully continue with clinic al trials that will lead to the release of the agents for clinical use in humans. PUBLIC HEALTH RELEVANCE: The proposed tantalum clusters may substantially improve X-ray imaging technology as an alternative contrast agent with improved contrast allowing su perior diagnostic imaging. They can potentially provide better imaging with smaller quantities of contrast agent, improved depth of penetration and reduced scattering, resulting in lower image noise as well as reduced radiation exposure. They can also prov ide better imaging for obese patients and an alternative contrast agent for patients allergic to iodine.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.